Biora Therapeutics, Inc. · OTC:BIORQ

Biora Therapeutics — EASD 2023 Short Oral Presentation

8 slides from Biora Therapeutics's conference presentation, October 2023

  1. Slide 1: Evaluation of the Pharmacokinetics of GLP-1 Receptor Agonist Delivered through the BioJet Platform

    635: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BioJet™ Oral Biotherapeutic Delivery Platform in a Porcine Model Jeff Smith, PhD Senior Director, Bioanalytical Sciences, Biora Therapeutics Authors: Shaoying Nikki Lee, Cheryl Stork, Re

  2. Slide 2: Needles Are Associated with Poor Disease Management

    NEEDLES ARE ASSOCIATED WITH POOR DISEASE MANAGEMENT 38 % of people with diabetes discontinue injectable medications due to injection concerns 1,2 of patients fail to maintain diabetes treatment 42 % due to injection concerns when using an injectable GLP-1 agonist2 higher discontinuation rate for dia

  3. Slide 3: BioJet Systemic Drug Delivery Platform

    BIOJET™ SYSTEMIC DRUG DELIVERY PLATFORM Needle-free, oral delivery to small intestine ORAL CAPSULE • Multivitamin size for ease of swallowing PRECISE DELIVERY • Enteric trigger for precise timing of drug delivery into the small intestine submucosal space for absorption into systemic circulation NEED

  4. Slide 4: Pre-clinical In Vivo Device Performance and PK Studies in Porcine Model

    4 PRE-CLINICAL IN VIVO DEVICE PERFORMANCE AND PK STUDIES IN PORCINE MODEL STUDY PROCEDURE THE BIOJET DEVICE • Porcine model selected due to similar anatomical and histological features to human Jet injection • BioJet™ device designed for human oral delivery Trigger module • Prolonged and variable ga

  5. Slide 5: Pharmacokinetics of Semaglutide Delivered via the BioJet Device in a Porcine Model

    PHARMACOKINETICS OF SEMAGLUTIDE DELIVERED VIA THE BIOJET™ DEVICE IN A PORCINE MODEL RESULTS • Average oral bioavailability vs IV administration of 37% ± 15% (N=7; CV:40%), ranging up to 60% † • A repeat study (PSS10) showed similar results with average oral bioavailability of 37% (N=5; CV:57%) • All

  6. Slide 6: Update: Recent Experiments with Next-Generation Autonomous Device Confirm Consistent Performance

    UPDATE: RECENT EXPERIMENTS WITH NEXT-GENERATION AUTONOMOUS DEVICE CONFIRM CONSISTENT PERFORMANCE RESULTS • Device was advanced past the pyloric sphincter into the proximal duodenum for autonomous triggering • Average oral bioavailability vs IV administration of 20.5% ± 15.3% (N=22; CV = 74.6%) • 96%

  7. Slide 7: Conclusions

    CONCLUSIONS • Oral administration of the BioJet™ device achieved averages of 20-37% and as high as 60% bioavailability of a GLP-1 receptor agonist in animal experiments. • This is a magnitude greater than the currently marketed oral tablet, Rybelsus®, which has less than 1% bioavailability estimated

  8. Slide 8: Poster: Evaluation of the Pharmacokinetics of GLP-1 Receptor Agonist via BioJet

    Evaluation of the Pharmacokinetics of Glucagon-Li Delivered through the BioJet™ Oral Biotherapeutic Delivery Platform in a Porcine Model Shaoying Nikki Le Chris Wahl, Sharat Singh? °BloraTh ator weight formulation ots therapeu cameund (Figures. FIGURE 1. The Biodet device int the submuccsalspace of

Biora Therapeutics — EASD 2023 Short Oral Presentation on 6ix